Lakefront Biotherapeutics reported EUR-63.7M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
argenx SE USD 539M 6M Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
Genmab DKK 401M 186M Jun/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
GRIFOLS EUR 505M 32M Sep/2026
Hikma Pharmaceutical USD 369M 84M Dec/2024
Incyte USD 778.57M 410.6M Jun/2026
Merck EUR 1.68B 82.6M Sep/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novartis USD 8.62B 2.14B Sep/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
UCB EUR 1.6B 570M Dec/2025
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026